Evaluation of Breast Disorders - Gynecology and Obstetrics - Merck
4.9 (144) · $ 19.99 · In stock
Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) —dedicated to using leading-edge science to save and improve lives around the world. Learn more about the Merck Manuals and our commitment to Global Medical Knowledge.
Evolutionary histories of breast cancer and related clones
Cancers, Free Full-Text
Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy
Frontiers HPLC for simultaneous quantification of free mannose and glucose concentrations in serum: use in detection of ovarian cancer
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Cancers, Free Full-Text
Breast Cancer - Gynecology and Obstetrics - Merck Manuals Professional Edition
HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer - Modern Pathology
Converging and evolving immuno-genomic routes toward immune escape in breast cancer
Breast Cancer - Gynecology and Obstetrics - Merck Manuals Professional Edition
Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants
PDF) Developing the Evidence Base to Inform Best Practice: A Scoping Study of Breast and Cervical Cancer Reviews in Low- and Middle-Income Countries
What Is Obstetrics and Gynecology?
Evaluation of Breast Disorders - Gynecology and Obstetrics - Merck Manuals Professional Edition
PDF) 2O Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial
